Rockwell MEDICAL, Inc. (RMTI) intrinsic value & 10-year financials
Rockwell MEDICAL, Inc. (RMTI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 3.0% a year to $69.3M, with an average return on invested capital of -163.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $7.43
- Market cap
- $267.3M
- Revenue (FY2025)
- $69.3M
- Revenue growth (10-yr CAGR)
- 3.0%
- ROIC (10-yr avg)
- -163.2%
- Free cash flow (FY2025)
- -$1.2M
RMTI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $69.3M | -$5.3M | -$0.15 | -$1.2M | -6.8% | -14.5% |
| FY2024 | $101.5M | -$480.0K | -$0.03 | $3.2M | 0.6% | 2.4% |
| FY2023 | $83.6M | -$8.4M | -$0.37 | -$9.7M | -8.0% | -32.2% |
| FY2022 | $72.8M | -$18.7M | -$1.89 | — | -23.0% | -121.2% |
| FY2021 | $61.9M | -$32.7M | -$0.35 | — | -49.0% | -335.6% |
| FY2020 | $62.2M | -$30.9M | -$0.41 | — | -45.7% | -306.2% |
| FY2019 | $61.3M | -$34.1M | — | — | -56.3% | -335.0% |
| FY2018 | $63.4M | -$32.1M | — | — | -51.2% | — |
| FY2017 | $57.3M | -$25.9M | -$0.51 | — | -45.2% | — |
| FY2016 | $53.3M | -$19.8M | -$0.39 | — | -37.9% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ROCKWELL MEDICAL, INC. has demonstrated mature, steady growth, with revenue compounding at 3.0% annually over the past decade.
ROCKWELL MEDICAL, INC. has historically struggled to out-earn its cost of capital, averaging just -25.0% ROIC.
Over the decade, ROCKWELL MEDICAL, INC. shows that management has aggressively returned capital to shareholders by retiring 29.0% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ROCKWELL MEDICAL, INC. is modeled at 3.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-1.87 per share.